Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2017 · 10-Q
Revenue$68.00K$68.00K−71.2% vs Q1 2016 Net Income-$12.62M-$12.62MN/M vs Q1 2016 EPS Diluted-$0.08-$0.08N/M vs Q1 2016 Operating Income-$11,904,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Margins · derivedOperating margin-17505.9%−10099.5 pt vs Q1 2016
Net margin-18558.8%−15971.5 pt vs Q1 2016
ended Mar 31, 2017 · filed May 15, 2017 · 45 d after period end